Smruthi Organics
- Market cap
- ₹ 155 Cr.
- P/E
- 19.6x
- P/B
- 2.11x
- 52-week range
- 95 – 175.3
- ROE
- 5%
- ROCE
- 8%
- Dividend yield
- 1.1%
- Debt / equity
- 0.12
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Smruthi Organics Limited is an India-based active pharmaceutical ingredients (API) manufacturer serving pharmaceutical companies. The Company’s segments include Bulk Drugs and Drugs Intermediates and Formulation. It manufactures API products in the anti-diabetic, anti-hypertension and anti-infectives therapeutic categories. Its products include Amlodipine Besilate, Losartan Potassium, Telmisartan, Metformin HCL, S-Amlodipine Besilate, S-Amlodipine Malelate, Valsartan, Vildagliptin, Teneligliptin, Ciprofloxacin HCL, Diloxanide Furoate, Norfloxacin, Pefloxacin Mesylate, Ticagrelor, and others. It caters to both the Indian domestic as well as the rest of the world (ROW) markets, with clients spanning Asia, the Americas, and Africa. The Company has two manufacturing facilities in Solapur, India. The API facility is spread across 22-acre land.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Smruthi Organics against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.6 against a typical 34.3: cheaper than most peers (1st = cheapest).56th of 220
- Sales growth+55.4% against a typical +15.6% from a year earlier.28th of 197
- Share price, 3 months+25.1% against a typical 0%.31st of 200
- Size₹ 154.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).130th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 23 | 40 | 27 | 29 | 31 | 38 | 19 | 32 | 22 | 29 | 29 |
| Expenses | 25 | 25 | 36 | 27 | 27 | 27 | 33 | 19 | 27 | 18 | 25 | 23 |
| Operating Profit | 4 | −1 | 4 | 0 | 3 | 4 | 5 | 0 | 5 | 4 | 4 | 6 |
| OPM % | 15% | −5% | 10.3% | 1.7% | 9.8% | 13.3% | 12.3% | 1.5% | 15.9% | 18% | 13.4% | 19.8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | −0 | −0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 3 | −3 | 2 | −1 | 1 | 2 | 3 | −2 | 3 | 2 | 2 | 4 |
| Tax % | 22.6% | −22% | 30.7% | −26.4% | 31.9% | 35.4% | 18.6% | −28.6% | 27.7% | 14.6% | 39.6% | 25.7% |
| Net Profit | 2 | −2 | 2 | −1 | 1 | 1 | 2 | −1 | 2 | 1 | 1 | 3 |
| EPS in Rs | 1.81 | −2 | 1.33 | −0.8 | 0.68 | 1.29 | 1.95 | −0.96 | 1.8 | 1.22 | 0.93 | 2.52 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 3%
- 5 Years
- −4%
- 3 Years
- −10%
- TTM
- −5%
- 10 Years
- 18%
- 5 Years
- −26%
- 3 Years
- −3%
- TTM
- 131%
- 10 Years
- —
- 5 Years
- −18%
- 3 Years
- −9%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 7%
- 3 Years
- 5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Smruthi Organics | ₹ 145.00 | ₹ 155 Cr. | 19.6x | 2.1x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.3x | 5.5x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 85.8x | 13.4x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 73.8x | 19.5x | — | 13.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.2x | 3.4x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21x | 4.2x | — | 15.7% |
Management
- Eaga Purushotham
- Executive Chairman of the Board, Managing Director
- Eaga Swapnil
- Chief Financial Officer, Managing Director, Executive Director
- Urvashi D. Khanna
- Compliance Officer, Company Secretary
- Smruthi Purushottam Eaga
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.